Greisshammer M, Saydam G, Palandri F, et al. Ruxolitinib fort he treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. EHA 2017, abstract S784.
Ibrutinib plus R-CHOP bij jongere patiënt met ‘non-germinal center B-cell’ DLBCL?
jun 2019 | Lymfoom